Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission , as well as the burden of COVID-19 disease .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCorrespondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citation
Cited by
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
Zheng, C., Shao, W., Chen, X., Zhang, B., Wang, G., & Zhang, W. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.009 · Cited by 693
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641
Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen, K.-H., Jalil, S. M. S., Jaouni, S. H., Kawas, H., Khan, W. A., Vattoth, A. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2027160 · Cited by 406
(2021) · doi:10.1016/j.vaccine.2021.04.002 · Cited by 101
Paris, C., Perrin, S., Hamonic, S., Bourget, B., Roué, C., Brassard, O., Tadié, E., Gicquel, V., Bénézit, F., Thibault, V., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.043 · Cited by 62
Metadata
- Authors
- Jones, N. K., Rivett, L., Seaman, S., Samworth, R. J., Warne, B., Workman, C., Ferris, M., Wright, J., Quinnell, N., Shaw, A., Cambridge COVID-19 Collaboration, Amory, A., Baker, S., Bateman, E., Begum, A., Begum, M., Bradley, J., Brennan, M., Burn, H., Crofts, C., Chaudhry, A., Chaudhry, Y., Cooper, D. J., Dawson, S., Dougan, G., Feather, R., Free, L., Friel, K., Gildea, C., Georgana, I., Grimwade, L., Gupta, R., Hall, S., Hannan, S., Hayes, J., Hosaja, A., Hosmillo, M., Izuagbe, R., Jahun, A., James, L., Jardin, J., Kingston, N., Lear, S., Lyons, P. A., Maxwell, P. H., Mott, S., Mugavin, S., Mwiya, J., Peacock, S., Nallattil, R. P., Oloyede, K., Ouwehand, W. H., Page, E., Perez, M., Raine, T., Routledge, M., Saunders, C., Smith, K. G., Sparkes, D., Stafford, M., Summers, C., Tatsi, D., Thaventhiran, J. E., Thomas Johnson, S., Török, M. E., Toshner, M., Turner, L., Wall, K., Watson, K., Goodfellow, I. G., Lehner, P. J., Howes, R., Wright, G., Matheson, N. J., & Weekes, M. P.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2021-04-08
- Volume
- 10
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W3151850025
- Cited by
- 73
- References
- 3
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. https://app.cochat.ai/papers/10.7554/elife.68808
- The paper
- Jones, N. K., Rivett, L., Seaman, S., Samworth, R. J., Warne, B., Workman, C., Ferris, M., Wright, J., Quinnell, N., Shaw, A., Cambridge COVID-19 Collaboration, Amory, A., Baker, S., Bateman, E., Begum, A., Begum, M., Bradley, J., Brennan, M., Burn, H., . . . Weekes, M. P. (2021). Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. eLife. https://doi.org/10.7554/elife.68808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.